Silence Therapeutics (SLN) Stock Statistics & Valuation Metrics

Silence Therapeutics has a market cap or net worth of $206.40M. The enterprise value is ―.

Silence Therapeutics has 47,230,280 shares outstanding. The number of shares has decreased by -2.65% in one year.

Silence Therapeutics’s return on equity (ROE) is 0.34 and return on invested capital (ROIC) is -34.70%.

The current PE Ratio of Silence Therapeutics is -7.17. Silence Therapeutics’s PEG ratio is -0.08.

In the last 12 months, Silence Therapeutics had revenue of 43.26M and earned -45.31M in profits. Earnings per share was -0.33.

In the last 12 months, operating cash flow was -12.31M and capital expenditures -67.00K, giving a free cash flow of -32.08M billion.

Silence Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Silence Therapeutics upcoming earnings date is Aug 14, 2025, TBA Not Confirmed.

Silence Therapeutics as a current ratio of 11.14, with Debt / Equity ratio of 0.09%

In the past 12 months, Silence Therapeutics has paid 845.00K in taxes.

Silence Therapeutics EV to EBITDA ratio is -17.42, with an EV/FCF ratio of -12.58.

Silence Therapeutics has $147.33M in cash and marketable securities with £117.00K in debt, giving a net cash position of -$147.22M billion.

Gross margin is 76.01%, with operating margin of -146.38%, and net profit margin of -104.74%.

The average price target for Silence Therapeutics is $32.33, which is 11.43% higher than the current price. The consensus rating is Moderate Buy